Table 1.

Summary of proposed beneficial effects of co-administration of mangiferin alongside chemotherapeutic agents.

Chemotherapeutic Agent	Cell Line	Reference	Evidence
Oxaliplatin	HeLa, HT29, HL60	[48]	Reduction in oxaliplatin IC50 values; counteracts resistance to oxaliplatin.
Etoposide	HL60, U937	[11,13]	Reduces oxidative stress. Protects normal cells without reducing sensitivity of HL60 to etoposide [13]. Activity of the drug is enhanced by mangiferin [11].
Doxorubicin	MCF7, U937	[13,33]	At high concentrations mangiferin can inhibit P-glycoprotein expression and chemosensitise for doxorubicin therapy [33]. Activity of the drug is enhanced by mangiferin [11].
Paclitaxel	Triple negative breast cancer	[60,62]	IRAK1 overexpression confers a growth advantage [62]. Mangiferin may inhibit IRAK1 activation [60,62].
Cisplatin	U937	[11]	Inhibits ROS production [8]. Activity of the drug is enhanced by mangiferin; Impedes NFκB activation; Enhanced cell death in the presence of TNF [11].
Vincristine	U937	[11]	Inhibits ROS production [8]. Activity of the drug is enhanced by mangiferin; Impedes NFκB activation; Enhanced cell death in the presence of TNF [11].
Adriamycin	U937	[11]	Inhibits ROS production [8]. Activity of the drug is enhanced by mangiferin; Impedes NFκB activation; Enhanced cell death in the presence of TNF [11].
AraC	U937	[11]	Inhibits ROS production [8]. Activity of the drug is enhanced by mangiferin; Impedes NFκB activation; Enhanced cell death in the presence of TNF [11].